Association Between Early Prostacyclin Therapy and Extracorporeal Life Support Use in Patients With Congenital Diaphragmatic Hernia
JAMA Pediatrics · 2023
DOI: 10.1001/jamapediatrics.2023.0405 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Pediatrics, 2023. Verfasst von Akila B Ramaraj und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric General and Thoracic Surgery, Seattle Children's Hospital, Seattle, Washington. Hauptthemen laut MEDLINE: Hernias, Diaphragmatic, Congenital, Extracorporeal Membrane Oxygenation, Hypertension, Pulmonary. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Prostacyclin (PGI 2 ) is a therapeutic option to treat congenital diaphragmatic hernia (CDH)–associated pulmonary hypertension in neonates. Its use may decrease the need for extracorporeal life support (ECLS).
Objective
To evaluate the association of early PGI 2 therapy with ECLS use and outcomes among patients with CDH. Design, Setting, and Participants This was a cohort study from the CDH Study Group (CDHSG) registry of patients born from January 2007 to December 2019. Patients were from 88 different tertiary pediatric referral centers worldwide that contributed data to the CDHSG. Patients were included in the study if they were admitted within the first week of life. Propensity score matching was performed using estimated gestational age, birth weight, transfer status, 1-minute and 5-minute Apgar scores, highest and lowest partial pressure of arterial carbon dioxide in the first 24 hours of life, and degree of pulmonary hypertension as covariates to generate a matched cohort of exposed and unexposed patients. Data were analyzed from January 2021 to December 2022. Exposures Early PGI 2 therapy was defined as initiation of PGI 2 within the first week of life. Patients who received ECLS were included in the early PGI 2 group if PGI 2 was started prior to ECLS. Main Outcomes and Measures The primary outcome of the study was the proportion of patients receiving ECLS in the exposed and unexposed groups.
Results
Of 6227 patients who met inclusion criteria (mean [SD] gestational age, 37.4 [2.36] weeks; 2618 [42%] female), 206 (3.3%) received early PGI 2 therapy. ECLS was used in 46 of 206 patients who received PGI 2 (22.2%) and 1682 of 6021 who did not (27.9%). After propensity score matching, there were 147 patients in the treatment and control groups. Thirty-four patients who received PGI 2 (23.3%) and 63 who did not (42.9%) received ECLS. Those who received PGI 2 were less likely to receive ECLS (adjusted odds ratio, 0.39; 95% CI, 0.22-0.68) and had shorter mean (SD) duration of ECLS (8.6 [3.73] days vs 12.6 [6.61] days; P < .001), although there was no significant difference in in-hospital mortality. Conclusions and Relevance In this study, there was decreased use of ECLS and decreased ECLS duration among patients with CDH who started PGI 2 therapy during the first week of life. These results identify a potential advantage of early prostacyclin therapy in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Pediatric General and Thoracic Surgery, Seattle Children's Hospital, Seattle, Washington.
- Department of General Surgery, UConn Health, Farmington, Connecticut.
- Department of Pediatrics, Division of Cardiology, University of Washington, Seattle.
- Pulmonary Hypertension Program, Heart Center, Seattle Children's Hospital, Seattle, Washington.
- Comprehensive Center for Congenital Diaphragmatic Hernia Care, University of Texas Health Science Center at Houston, Houston.
Zitieren
APA
Ramaraj, A. B., Rice-Townsend, S. E., Foster, C. L., Yung, D., Jackson, E. O., Ebanks, A. H., Harting, M. T., Stark, R. A., & Congenital Diaphragmatic Hernia Study Group (2023). Association Between Early Prostacyclin Therapy and Extracorporeal Life Support Use in Patients With Congenital Diaphragmatic Hernia. JAMA Pediatrics. https://doi.org/10.1001/jamapediatrics.2023.0405
Vancouver
Ramaraj AB, Rice-Townsend SE, Foster CL, Yung D, Jackson EO, Ebanks AH, et al. Association Between Early Prostacyclin Therapy and Extracorporeal Life Support Use in Patients With Congenital Diaphragmatic Hernia. JAMA Pediatrics. 2023. doi:10.1001/jamapediatrics.2023.0405
BibTeX
@article{Ramaraj2023,
author = {Ramaraj, Akila B and Rice-Townsend, Samuel E and Foster, Carrie L and Yung, Delphine and Jackson, Emma O and Ebanks, Ashley H and Harting, Matthew T and Stark, Rebecca A and Congenital Diaphragmatic Hernia Study Group, Congenital Diaphragmatic Hernia Study Group},
title = {Association Between Early Prostacyclin Therapy and Extracorporeal Life Support Use in Patients With Congenital Diaphragmatic Hernia},
journal = {JAMA Pediatrics},
year = {2023},
doi = {10.1001/jamapediatrics.2023.0405}
}
EUVIMED